Mycapssa

Acromegaly Maintenance

Mycapssa is an oral medication used to manage acromegaly, a hormonal disorder that occurs when the pituitary gland produces too much growth hormone. This excess hormone can cause bones and tissues in the hands, feet, and face to grow larger than normal.

This medication is specifically used as a maintenance therapy for patients who meet the following conditions:

• They have already been treated with injectable somatostatin analogs, such as octreotide or lanreotide.
• They have shown a positive response to these injectable treatments.
• They have tolerated the injectable medications well.

The goal of treatment is to maintain growth hormone and insulin-like growth factor-1 (IGF-1) at stable, healthy levels to control the symptoms of the disease.

Mechanism of Action

Mycapssa contains octreotide, which is a synthetic version of a hormone called somatostatin that occurs naturally in the body. In people with acromegaly, the pituitary gland produces too much growth hormone, which in turn causes the liver to produce high levels of insulin-like growth factor-1 (IGF-1).

Octreotide works by binding to specific sites, called somatostatin receptors, on cells in the pituitary gland and other parts of the body. When it attaches to these receptors, it sends a signal to stop the release of:

• Growth hormone
• Insulin-like growth factor-1 (IGF-1)
• Certain digestive hormones and enzymes

By lowering the levels of these hormones, the medication helps manage the symptoms of acromegaly and keeps hormone levels within a target range. The oral capsule is specially formulated to allow the medication to be absorbed through the lining of the intestine and enter the bloodstream.

Common Side Effects

Many people taking Mycapssa experience mild to moderate side effects. These often include:

• Nausea and vomiting
• Diarrhea or constipation
• Stomach pain, gas, or bloating
• Headache
• Joint or muscle pain
• Fatigue or weakness
• Dizziness
• Increased sweating

Serious Side Effects

While less common, Mycapssa can cause serious health problems. Contact your healthcare provider immediately if you experience:

• Gallbladder problems: Symptoms include sudden, severe pain in the upper right stomach area, fever, chills, and yellowing of the skin or eyes (jaundice).
• Heart rhythm changes: A slow heart rate (bradycardia) or feeling like your heart is skipping a beat.
• Thyroid issues: Symptoms of an underactive thyroid, such as weight gain, cold intolerance, or dry skin.
• Blood sugar changes: Both high blood sugar (increased thirst and urination) and low blood sugar (shakiness, sweating, or confusion) can occur.
• Vitamin B12 deficiency: Long-term use may lower vitamin B12 levels in the body.

Gallbladder Problems

Octreotide can cause the formation of gallstones or gallbladder sludge. Healthcare providers may perform periodic ultrasounds of the gallbladder to monitor for these issues while using this medication.

Blood Sugar Changes

This medication can affect how the body manages blood sugar, leading to either high blood sugar (hyperglycemia) or low blood sugar (hypoglycemia). People with diabetes may need to monitor their blood glucose levels more frequently, and their diabetes medications might require adjustment during treatment.

Thyroid Function

Mycapssa can suppress thyroid function, leading to hypothyroidism (low thyroid hormone levels). Periodic blood tests to check thyroid-stimulating hormone (TSH) levels are typically recommended to monitor for these changes.

Heart Rate and Rhythm

Some individuals may experience a slow heart rate (bradycardia) or other changes in heart rhythm while taking this medication. Monitoring may be necessary for those with pre-existing heart conditions or those taking other medications that affect heart rate.

Vitamin B12 Levels

Long-term use of octreotide may decrease the absorption of vitamin B12, potentially leading to a deficiency over time. Healthcare providers may monitor B12 levels during treatment to ensure they remain within a healthy range.

Pregnancy and Fertility

In women with acromegaly, treatment with octreotide may restore fertility by normalizing hormone levels, which increases the risk of unintended pregnancy. It is important to discuss effective contraception methods with a healthcare provider during treatment.

Pregnancy

Data regarding the use of Mycapssa in pregnant women are insufficient to determine if the medication causes birth defects, miscarriage, or other adverse effects. While animal studies have not shown evidence of harm to the fetus, human studies are lacking. If you are pregnant or planning to become pregnant, consult your doctor to discuss the potential benefits and risks.

Fertility and Contraception

In women with acromegaly, treatment with octreotide may lead to changes in hormone levels that could increase fertility and the likelihood of becoming pregnant. Because of this, healthcare providers typically recommend using effective birth control during treatment to prevent unintended pregnancy.

Breastfeeding

It is not known if octreotide passes into human breast milk. There is also no information available regarding its effects on a breastfed infant or on milk production. Individuals should consult with their doctor to weigh the benefits of breastfeeding against the potential risks to the infant while taking this medication.

Dosage Forms

Mycapssa is available in the following form:

• Delayed-release capsules: These are oral capsules designed to release the medication in the intestines rather than the stomach.

FDA Approval History

The U.S. Food and Drug Administration (FDA) approved Mycapssa (octreotide delayed-release capsules) on June 26, 2020. This approval provided the first oral alternative to somatostatin analog injections for patients with acromegaly.

Approved Indications

Mycapssa is indicated for the long-term maintenance treatment of acromegaly in patients who have previously demonstrated a clinical response to and tolerated treatment with octreotide or lanreotide. The goal of treatment is to maintain biochemical control of growth hormone and insulin-like growth factor-1 (IGF-1) levels.

Regulatory Status and Safety

There are no boxed warnings or Risk Evaluation and Mitigation Strategies (REMS) required for this medication. The FDA-approved labeling includes recommendations for periodic monitoring of certain health parameters during therapy, including:

• Gallbladder health via ultrasound to check for gallstones.
• Blood glucose levels, as the drug may affect insulin and glucagon secretion.
• Thyroid function tests.
• Vitamin B12 levels.
• Heart rate monitoring in patients with certain cardiac conditions.

Insurance and Prior Authorization

Mycapssa is classified as a specialty medication. Most insurance plans, including private insurance and Medicare, typically require prior authorization before covering the drug. This means your healthcare provider must submit documentation to your insurance company to confirm that the medication is medically necessary for your condition.

Specialty Pharmacy Requirements

Unlike many common medications, Mycapssa is usually not available at local retail pharmacies. It is typically dispensed through specialty pharmacies that handle medications for rare or complex conditions. These pharmacies coordinate with your insurance and may deliver the medication directly to your home.

Financial Assistance Programs

The manufacturer may offer patient assistance programs or co-pay savings cards to help reduce out-of-pocket costs for eligible patients. These programs are often designed for those with commercial insurance, while patients with government-funded insurance like Medicare or Medicaid may need to look for different types of charitable assistance.

Factors Affecting Out-of-Pocket Costs

• Insurance Plan Type: Your specific deductible, co-insurance, or co-payment requirements will determine your final cost.
• Dosage: While the price is often set per capsule, the total monthly cost may depend on the specific dosage prescribed by your doctor.
• Coverage Gaps: For those on Medicare, costs may change if you enter the coverage gap (often called the "donut hole").